Denileukin diftitox: A concise clinical review

Expert Review of Anticancer Therapy

Volumn 5, Issue 1, 2005, Pages 33-38

  Eklund, John W ^a   Kuzel, Timothy M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cutaneous T cell lymphoma; DAB389IL 2; Denileukin diftitox; Diphtheria toxin; Fusion protein; Ontak

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; CORTICOSTEROID; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DIPHENHYDRAMINE; DIPHTHERIA TOXIN; ELONGATION FACTOR 2; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; PARACETAMOL; PREDNISONE; PROTEIN P55; PROTEIN P75; RETINOID; STEROID;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BACKACHE; BINDING AFFINITY; BONE MARROW SUPPRESSION; CAPILLARY LEAK SYNDROME; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FLUSHING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; IMMUNOMODULATION; KIDNEY TUMOR; LIVER TOXICITY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MYALGIA; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PRURITUS; PSORIASIS; RECEPTOR BINDING; RELAPSE; REVIEW; SOLID TUMOR; SURVIVAL RATE; SYSTEMATIC REVIEW; T CELL DEPLETION; THORAX DISEASE; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DIPHTHERIA TOXIN; GRAFT VS HOST DISEASE; HUMANS; INTERLEUKIN-2; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL, CUTANEOUS; PSORIASIS; RECOMBINANT FUSION PROTEINS; SURVIVAL;

EID: 14244262178     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.1.33     Document Type: Review

References (26)

1. Williams DP, Parker K, Bacha P et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1, 493-498 (1987).
2. Bacha P, Williams DP, Waters C et al. Interleukin-2 receptor-targeted cytotoxicity. Interleukin-2 receptor-mediated action of a diphtheria toxin-related interleukin-2 fusion protein. J. Exp. Med. 167, 612-622 (1988).
3. Kiyokawa T, Williams DP, Snider CE et al. Protein engineering of DAB-IL-2 fusion toxins to increase biologic potency. Ann. NY Acad. Sci. 636, 331-339 (1991).
4. LeMaistre CF, Saleh MN, Kuzel TM et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91, 399-405 (1998).
5. Morris RE, Gerstein AS, Bonventre PF et al. Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation. Infect. Immun. 50, 721-727 (1985).
6. Moya M, Dautry-Varsat A, Goud B et al. Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin. J. Cell Biol. 101, 548-559 (1985).
7. +-ATPase in regulating ATP-dependent endosome acidification. Proc. Natl Acad. Sci. USA 86, 539-543 (1989).
8. Kuzel TM, Rosen ST, Gordon LI et al. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk. Lymphoma 11, 369-377 (1993).
9. LeMaistre CF, Craig FE, Meneghetti C et al. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res. 53, 3930-3934 (1993).
10. LeMaistre CF, Meneghetti C, Rosenblum M et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood. 79, 2547-2554 (1992).
11. Hesketh P, Caguioa P, Koh H et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 11, 1682-1690 (1993).
12. Olsen E, Duvic M, Frankel A et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376-388 (2001).
13. Foss FM, Bacha P, Osann KE et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, Ontak) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma 1, 298-302 (2001).
14. Chin KM, Stark P, Foss FM. Outcomes in cutaneous T-cell lymphoma patients treated with denileukin diftitox. Proc. Am. Soc. Clin. Oncol. 22, 591 (2003) (Abstract 2376).
15. 389IL-2 (Ontak) cytotoxicity in leukemia and lymphoma by arginine butyrate and all-trans retinoic acid. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 66).
16. Dang NH, Hagemeister F, Fayad L et al. Interim analysis of a Phase II study of denileukin diftitox (Ontak) for B and T-cell non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. 22, 570 (2003) (Abstract 2292).
17. Dang NH, Hagemeister FB, Pro B et al. Phase II Study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin. Oncol. 22, 4095-4102 (2004).
18. Frankel AE, Fleming DR, Hall PD et al. A Phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin. Cancer Res. 9, 3555-3561 (2003).
19. Morgan SJ, Seymour JF, Prince HM, Westerman DA, Wolf MM. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clin. Cancer Res. 10, 3572-3575 (2004).
20. Gerena Lewis MA, R Shukla, Kleykamp B, Jazieh AR, Hainsworth J. A Phase II trial of denileukin diftitox - in previously treated, advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 7292).
21. 389IL-2, for the treatment of psoriasis. Dermatol. Ther. 5, 48-63 (1998).
22. 389IL-2 to patients with recalcitrant psoriasis: a double-blind, Phase II multicenter trial. J. Am. Acad. Dermatol. 38, 938-944 (1998).
23. Martin A, Gutierrez E, Muglia J et al. A multicenter dose-escalation trial with denileukin diftitox (Ontak, DAB(389)IL-2) in patients with severe psoriasis. J. Am. Acad. Dermatol. 45, 871-881 (2001).
24. Ho VT, Zahrieh D, Hochberg E et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft versus host disease after allogeneic hematopoietic stem cell transplantation. Blood 104, 1224-1226 (2004).
25. + regulatory T-cells. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 2506).
26. Pichardo DA, Querfeld C, Guitart J et al. Cutaneous T-cell lymphoma: a paradigm for biological therapies. Leuk. Lymphoma 45, 1755-1765 (2004).